A startup incubated at UNIST has successfully listed on the KOSDAQ, marking a significant milestone in the university’s efforts to translate research into commercially viable technologies and foster globally competitive ventures.
RecensMedical Inc., a faculty-founded startup established in 2016, began trading on the KOSDAQ on March 31, 2026. The company is based on proprietary research developed in the laboratory of Professor Gun-Ho Kim of the Department of Mechanical Engineering at UNIST. The company specializes in precision cooling-based medical devices for dermatology, ophthalmology, and veterinary applications. Its core technology enables real-time monitoring of tissue temperature and precise control of cooling intensity and duration, offering an alternative to conventional chemical anesthesia by reducing patient discomfort and improving procedural efficiency.
“RecensMedical exemplifies how UNIST’s foundational research can be transformed into impactful, market-ready solutions,” said Professor Gun-Ho Kim, CEO of RecensMedical Inc. “We will continue to accelerate global expansion by securing regulatory approvals and strengthening international distribution channels.”
The company’s public listing underscores the effectiveness of UNIST’s R&D Scale-Up Strategy, which integrates the full innovation pipeline—from fundamental research and intellectual property development to startup incubation, manufacturing, and global market entry.
UNIST has systematically supported technology commercialization by building strong patent portfolios from early-stage research, providing on-campus incubation infrastructure, and offering programs for prototyping, investment attraction, and overseas expansion.
RecensMedical Inc. benefited from this ecosystem throughout its growth. In particular, UNIST’s GMP-certified manufacturing facilities played a critical role in securing regulatory approval from the Ministry of Food and Drug Safety (MFDS), enabling both product validation and commercialization.
The company has also achieved steady growth through continued institutional and external support. It was selected as the first TIPS (Tech Incubator Program for Startup) in Ulsan in 2017 and later secured investment from a fund managed by UNIST Holdings in 2022. Additional support was provided through the Ulsan-Ulju INNOTOWN, where UNIST serves as a core technology institution. The initiative offers access to advanced research infrastructure, demonstration facilities, and R&BD funding, while facilitating connections to private investment and global mentoring networks.
President Chong Rae Park stated, “UNIST’s R&D Scale-Up Strategy emphasizes commercialization from the earliest stages of research. RecensMedical’s growth demonstrates how integrated support—from technology validation to global collaboration—can translate research into real industrial impact. We will continue to strengthen an innovation ecosystem that connects research, industry, and global markets.”
RecensMedical Inc. has developed a portfolio of precision cooling devices designed to reduce pain and shorten treatment time across multiple clinical fields. Its flagship products include TargetCool for dermatology, OcuCool for ophthalmology, and VetEase for veterinary care. Following its KOSDAQ debut, the company is positioned to accelerate global commercialization and further establish itself as a leader in precision cooling medical technology.
